Holocene Advisors, LP Macrogenics Inc Transaction History

Holocene Advisors, LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $29.6 Million - $43.1 Million	-1,500,096 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $30.7 Million - $53.4 Million	1,500,096 New	1,500,096 $40.3 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.